Zepbound Delayed-Onset Side Effects: What Takes Weeks or Months to Show Up

Which Zepbound side effects arrive late?

The label's one explicit timing statement concerns the stomach and bowel: the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1]. In the pooled weight trials, 56% of patients on every Zepbound dose reported a gastrointestinal adverse reaction versus 30% on placebo. Severe GI reactions were reported by 1.7% on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg versus 1% on placebo [1].

The label separately warns about acute gallbladder disease, acute pancreatitis, acute kidney injury from volume depletion, serious hypersensitivity, and the thyroid C-cell risk in the boxed warning [1]. Its text gives rates for these over trials of up to 72 weeks, but no time to onset for gallbladder events or hair loss; it says only that both were associated with weight reduction [1].

Gallbladder disease

The label's pooled weight-trial figures (Studies 1 and 2) are cholelithiasis 1.1% with Zepbound versus 1% with placebo, cholecystitis 0.7% versus 0.2%, and cholecystectomy 0.2% versus none on placebo [1]. The label lists acute gallbladder disease as a warning and states that acute gallbladder events were associated with weight reduction [1]. It also says that if cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated [1].

Hair loss

Hair loss appears in the label's table of common adverse reactions: 5% on 5 mg, 4% on 10 mg and 5% on 15 mg versus 1% on placebo [1]. The label says hair loss was associated with weight reduction and was more frequent in women: 7.1% of women versus 0.5% of men on Zepbound, compared with 1.3% of women and 0% of men on placebo [1].

No Zepbound-treated patient in those trials stopped treatment for hair loss; one placebo-treated patient did [1].

Pancreatitis

The label warns that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Zepbound [1]. After initiation, the label says to observe patients carefully for signs and symptoms, which may include persistent or severe abdominal pain (sometimes radiating to the back) with or without nausea or vomiting, and to discontinue Zepbound and initiate appropriate management if pancreatitis is suspected [1].

In the pooled weight trials, 0.2% of Zepbound-treated patients had adjudication-confirmed acute pancreatitis versus 0.2% of placebo patients, or 0.14 versus 0.15 patients per 100 years of exposure [1]. In tirzepatide trials for a different indication, 14 adjudicated events occurred in 13 tirzepatide-treated patients (0.23 per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 per 100 years) [1]. In the obstructive sleep apnea trials the exposure-adjusted rate was 0.84 per 100 years with Zepbound versus 0 with placebo [1].

Acute kidney injury

The kidney risk described in the label is indirect. Postmarketing reports describe acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Zepbound, and the majority of those events occurred in patients who had gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting or diarrhea [1].

The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [1]. Separately, no dose adjustment is recommended for renal or hepatic impairment [1].

The thyroid C-cell warning

This is the boxed warning, and it is based on animal data. In rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [1]. The label states that it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because human relevance has not been determined [1].

Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1]. The label asks prescribers to counsel patients about the potential risk and about symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, difficulty breathing, or persistent hoarseness [1].

On monitoring, the label states that routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma, and that such monitoring may increase unnecessary procedures because of low test specificity and the high background rate of thyroid disease [1]. It notes that significantly elevated calcitonin may indicate medullary thyroid carcinoma, with values usually above 50 ng/L, and that an elevated calcitonin or a thyroid nodule found on examination or imaging should be further evaluated [1].

What happens to fat and lean tissue

In a body-composition substudy of SURMOUNT-1, 160 participants had DXA scans at baseline and week 72 (124 pooled tirzepatide, 36 placebo; 73% female; mean weight 102.5 kg) [2]. Body weight changed by -21.3% with tirzepatide versus -5.3% with placebo, fat mass by -33.9% versus -8.2%, and lean mass by -10.9% versus -2.6% [2]. About 75% of the weight lost was fat mass and about 25% was lean mass in both groups, and those proportions held across most subgroup analyses [2].

The label itself says tirzepatide lowers body weight with greater fat mass loss than lean mass loss, and gives no lean-mass figures [1]. Two limits apply to the substudy: it was small, and DXA cannot separate muscle from other lean tissue [2].

Effects tied to each dose step

The label's clearest repeating-timing statement involves oral contraception. Zepbound delays gastric emptying, with the largest delay after the first dose, and the label advises people using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation; non-oral hormonal contraceptives should not be affected [1]. In a pharmacokinetic study with a single 5 mg dose and a combined pill containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate, peak levels of ethinyl estradiol, norgestimate and norelgestromin fell 59%, 66% and 55%, total exposure fell 20%, 21% and 23%, and time to peak was delayed by 2.5 to 4.5 hours [1].